Efficacy and safety of abatacept in RA patients in daily clinical practice: An retrospective observational study

Efficacy and safety of abatacept in RA patients in daily clinical practice: An retrospective observational study - Abatacept leading Trial for RA on Imaging Remission

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000008285

Enrollment

Registered

2012-06-28

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Rheumatoid arthritis diagnosed by ACR/EULAR new classification criteria for RA (2)Meet the criteria for Abatacept Post Marketing Surveillance in Japan.

Exclusion criteria

Exclusion criteria: Patients who are inadequate by investigator's decision.

Design outcomes

Primary

Measure	Time frame
Percentages of structural remission (modified total Sharp score [mTSS]=/<0) at week 24 and at week 52 after abatacept treatment.	—

Secondary

Measure	Time frame
Percentages of clinical remission (Simplified Disease Activity Index[SDAI]=/<3.3) and functional remission (health assessment questionnaire [HAQ]=/<0.5) at week 24 and week 52 after abatacept treatment	—

Countries

Japan

Contacts

Public ContactYusuke Miyazaki

University of Occupational and Environmental Health, Japan The First Department of Internal Medicine, School of Medicine

yuppy0316@med.uoeh-u.ac.jp0936031611

Outcome results